Pathogenesis and Management of Intestinal Failure-Associated Liver Disease
Seminars in Liver Disease · 2025-03 · 45 (01) · 066-080
DOI: 10.1055/a-2545-7370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 18.03.2025. Verfasst von Sasha-Jane Abi-Aad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of South Florida Morsani College of Medicine, …. Hauptthemen laut MEDLINE: Parenteral Nutrition, Liver Diseases, Intestinal Failure. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Long-term parenteral nutrition (PN) has considerably improved the management of intestinal failure (IF) in children and adults, particularly those with short bowel syndrome; however, it carries a significant risk of hepatotoxicity, specifically, intestinal failure-associated liver disease (IFALD), also known as PN-associated liver disease. This review provides an update on the latest understanding of IFALD pathogenesis, emerging therapies, and ongoing challenges in the management of this complication. A number of factors are associated with the development of IFALD. PN lipid emulsions, phytosterol exposure, bacterial dysbiosis, an altered gut–liver axis, and episodes of sepsis disrupt bile acid homeostasis and promote liver inflammation in the active phase of IFALD, favoring the development of PN-associated cholestasis (PNAC) and the more chronic form of steatohepatitis with fibrosis. Based on the identification of pathophysiological pathways, potential therapies are being studied in preclinical and clinical trials, including lipid emulsion modifications; targeted therapies such as Farnesoid X receptor (FXR) and liver receptor homolog 1 (LRH-1) agonists, tumor necrosis factor inhibitors, glucagon-like peptide-2 analogs; microbiome modulation; and supplementation with choline and antioxidants. In conclusion, the pathogenesis of IFALD is complex, and PN dependence and liver injury remain challenging, particularly in patients with IF who cannot advance to enteral nutrition and be weaned off PN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, Florida.
- Department of Pathology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
- Department of Pediatrics, Digestive Health Institute, Children's Hospital Colorado, Section of Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Aurora, Colorado.
ORCID-Profile: Sasha-Jane Abi-Aad, Mark Lovell, Racha T Khalaf, Ronald J Sokol
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- Cystic Fibrosis Foundation
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Center for Advancing Translational Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Abi-Aad, S. J., Lovell, M., Khalaf, R. T., & Sokol, R. J. (2025). Pathogenesis and Management of Intestinal Failure-Associated Liver Disease. Seminars in Liver Disease, 45(01), 066-080. https://doi.org/10.1055/a-2545-7370
Vancouver
Abi-Aad SJ, Lovell M, Khalaf RT, Sokol RJ. Pathogenesis and Management of Intestinal Failure-Associated Liver Disease. Seminars in Liver Disease. 2025;45(01):066-080. doi:10.1055/a-2545-7370
BibTeX
@article{AbiAad2025,
author = {Abi-Aad, Sasha-Jane and Lovell, Mark and Khalaf, Racha T and Sokol, Ronald J},
title = {Pathogenesis and Management of Intestinal Failure-Associated Liver Disease},
journal = {Seminars in Liver Disease},
year = {2025},
volume = {45},
number = {01},
pages = {066--080},
doi = {10.1055/a-2545-7370}
}
EUVIMED